Functional precision medicine profiling of patient-derived organoids identifies effective targeted therapies for patients with low-grade serous ovarian carcinoma
Elizabeth M. Swisher(University of Washington), Carla Grandori(Precision for Medicine (United States)), Lauren Appleyard(Precision for Medicine (United States)), Jill Alldredge(Advanced Emissions Solutions (United States)), Renata R. Urban(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Soledad Jorge(University of Washington), Heidi J. Gray(Seattle Cancer Care Alliance), Barbara A. Goff(University of Washington), Payel Chatterjee(Precision for Medicine (United States)), Marwah Al-Aloosi(Precision for Medicine (United States)), Elise J. Simons(University of Washington), Christopher J. Kemp(Fred Hutch Cancer Center), Areej Alhareeri(University of Washington)
Cited by 0
Related Papers
The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior
|Annual Review of Cell and Developmental Biology|2000|1.3k
Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
|Cancer Discovery|2017|964
Direct activation of TERT transcription by c-MYC
|Nature Genetics|1999|903
Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion
|Proceedings of the National Academy of Sciences|2000|827
c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I
|Nature Cell Biology|2005|671